Biological Significance of the Biofield Energy Treatment Based Test Formulation on Various Biomarkers Using Cell-Based Assays

Journal: Journal of Pharmacy and Pharmaceutics  Web

Published: July 27, 2019 Volume: 6 Issue: 1 Pages: 49-58

DOI: 10.15436/2377-1313.19.2520 ISSN: 2377-1313

Authors: Dimitrius Anagnos, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana

Citation: Anagnos, D., et al. Biological Significance of the Biofield Energy Treatment Based Test Formulation on Various Biomarkers Using Cell-Based Assays (2019) J pharma pharmaceutics 6(1): 49-58.

  • 24 Views
  • 1 Downloads

Abstract

The aim of the present study determined the impact of the Biofield Energy Treated test formulation using cell lines related with vital organs functioning. Different cells based assay were used based on the vital organs function of bones, heart, liver, lungs, and brain. The test formulation and cells media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Dimitrius Anagnos, USA and were labeled as the Biofield Energy Treated (BT) test formulation / media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell line. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 25.6% (at 63.75 μg/mL), 46.7% (at 0.1 μg/mL), and 109.5% (at 63.75 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 41.3%, 22.8%, and 34.8% at 63.75 μg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cytoprotective activity in human hepatoma cells (HepG2) showed improved cell viability by 117.7% (at 0.1 μg/mL), 61.3% (at 25.5 μg/mL), and 104% (at 0.1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 105.7% at 10 μg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 368% and 602% at 0.1 μg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups respectively, as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 58.8% at 1 μg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 32.6% at 25 μg/mL, and improved cellular protection by 60.4% and 109.5% at 25 and 63.75 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.9% (at 10 μg/mL), 84.2% (at 25.5 μg/mL), and 87.6% (at 10 μg/mL) in the UT-Med + BTTI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 35.2% (at 0.1 μg/mL), 35.2% (at 0.1 μg/mL), and 79.7% (at 1 μg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased at 25 μg/mL by 30.6%, 107.7%, and 89.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased at 50 μg/mL by 156.1%, 158.7%, and 68.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The test formulation was tested in different cell lines for multiple organ health analysis using combinations with the Biofield Energy Treated and untreated test formulation groups. The MTT assay showed that the test formulation was found safe and non-toxic against all the tested cell lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 25.6% (at 63.75 μg/mL), 46.7% (at 0.1 μg/mL), and 109.5% (at 63.75 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability was 41.3% at 63.75 μg/mL in the UT-Med + BT-TI group, and the test formulation in A549 cells showed maximum restoration of cell viability by 117.7% at 0.1 μg/mL in the BT-Med + BT-TI group as compared with the untreated test group. Similarly, ALP activity in MG-63 cells showed significantly increased ALP activity at 10 μg/mL by 105.7%, 50.5%, and 99% in UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the UTMed + UT-TI group. Similarly, ALP activity in Ishikawa cells with maximum cellular protection was reported at 0.1 μg/mL by 368% and 602% in UT-Med + BT-TI and BT-Med + BT-TI group test groups, respectively, as compared with the untreated test group. The LDH activity was significantly decreased and the data was presented in increased percentage cellular protection data, which showed maximum cellular protection by 58.8% (at 1 μg/mL), 32.6% (at 25 μg/mL), and 60.4% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BTTI groups respectively, as compared to the untreated test group. ALT activity was studied and data showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 35.9% (at 10 μg/mL), 84.2% (at 25.5 μg/mL), and 87.6% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 35.2% (at 0.1 μg/mL), 35.2% (at 0.1 μg/mL), and 79.7% (at 1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 30.6% (at 25 μg/mL), 107.7% (at 25 μg/mL), and 89.1% (at 25 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 136.3%, and 156.1% in the UT-Med + BT-TI group at 10 and 50 μg/mL respectively, while 98.8%, and 158.7% increased RQ of VDR at 10 and 50 μg/mL respectively, in the BT-Med + UT-TI group, and increased RQ of VDR by 26.8% and 68.1% at 10 and 50 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Thus, this experimental study concluded that the Biofield Energy based test formulation can improve the overall functioning of heart, liver, bones, neuronal, and lungs parameters against any oxidative stress or damage induced by free radicals. Thus, Biofield Energy Treatment (The Trivedi Effect®) can be used for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.